227 related articles for article (PubMed ID: 16873266)
1. Transposon-assisted cloning and traceless mutagenesis of adenoviruses: Development of a novel vector based on species D.
Ruzsics Z; Wagner M; Osterlehner A; Cook J; Koszinowski U; Burgert HG
J Virol; 2006 Aug; 80(16):8100-13. PubMed ID: 16873266
[TBL] [Abstract][Full Text] [Related]
2. The novel early region 3 protein E3/49K is specifically expressed by adenoviruses of subgenus D: implications for epidemic keratoconjunctivitis and adenovirus evolution.
Blusch JH; Deryckere F; Windheim M; Ruzsics Z; Arnberg N; Adrian T; Burgert HG
Virology; 2002 Apr; 296(1):94-106. PubMed ID: 12036321
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus vectors based on human adenovirus type 19a have high potential for human muscle-directed gene therapy.
Thirion C; Lochmüller H; Ruzsics Z; Boelhauve M; König C; Thedieck C; Kutik S; Geiger C; Kochanek S; Volpers C; Burgert HG
Hum Gene Ther; 2006 Feb; 17(2):193-205. PubMed ID: 16454653
[TBL] [Abstract][Full Text] [Related]
4. Human adenovirus type 35: nucleotide sequence and vector development.
Gao W; Robbins PD; Gambotto A
Gene Ther; 2003 Nov; 10(23):1941-9. PubMed ID: 14528318
[TBL] [Abstract][Full Text] [Related]
5. Development of a recombinant adenovirus vector production system free of replication-competent adenovirus by utilizing a packaging size limit of the viral genome.
Suzuki T; Sasaki T; Yano K; Sakurai F; Kawabata K; Kondoh M; Hayakawa T; Yagi K; Mizuguchi H
Virus Res; 2011 Jun; 158(1-2):154-60. PubMed ID: 21470569
[TBL] [Abstract][Full Text] [Related]
6. A capsid-modified adenovirus vector devoid of all viral genes: assessment of transduction and toxicity in human hematopoietic cells.
Stecher H; Shayakhmetov DM; Stamatoyannopoulos G; Lieber A
Mol Ther; 2001 Jul; 4(1):36-44. PubMed ID: 11472104
[TBL] [Abstract][Full Text] [Related]
7. Hybrid yeast-bacteria cloning system used to capture and modify adenoviral and nonviral genomes.
Hokanson CA; Dora E; Donahue BA; Rivkin M; Finer M; Mendez MJ
Hum Gene Ther; 2003 Mar; 14(4):329-39. PubMed ID: 12659674
[TBL] [Abstract][Full Text] [Related]
8. Early region 3-replacement adenovirus recombinants are less pathogenic in cotton rats and mice than early region 3-deleted viruses.
Berencsi K; Uri A; Valyi-Nagy T; Valyi-Nagy I; Meignier B; Peretz FV; Rando RF; Plotkin SA; Gönczöl E
Lab Invest; 1994 Sep; 71(3):350-8. PubMed ID: 7933985
[TBL] [Abstract][Full Text] [Related]
9. Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein.
Hodges BL; Serra D; Hu H; Begy CA; Chamberlain JS; Amalfitano A
J Gene Med; 2000; 2(4):250-9. PubMed ID: 10953916
[TBL] [Abstract][Full Text] [Related]
10. An adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent deltaE1-E2-E3-E4 Ad5 vectors.
Catalucci D; Sporeno E; Cirillo A; Ciliberto G; Nicosia A; Colloca S
J Virol; 2005 May; 79(10):6400-9. PubMed ID: 15858023
[TBL] [Abstract][Full Text] [Related]
11. Production of helper-dependent adenovirus vector relies on helper virus structure and complementing.
Zhou HS; Zhao T; Rao XM; Beaudet AL
J Gene Med; 2002; 4(5):498-509. PubMed ID: 12221643
[TBL] [Abstract][Full Text] [Related]
12. A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy.
Stoff-Khalili MA; Rivera AA; Glasgow JN; Le LP; Stoff A; Everts M; Tsuruta Y; Kawakami Y; Bauerschmitz GJ; Mathis JM; Pereboeva L; Seigal GP; Dall P; Curiel DT
Gene Ther; 2005 Dec; 12(23):1696-706. PubMed ID: 16034451
[TBL] [Abstract][Full Text] [Related]
13. Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host.
Poller W; Schneider-Rasp S; Liebert U; Merklein F; Thalheimer P; Haack A; Schwaab R; Schmitt C; Brackmann HH
Gene Ther; 1996 Jun; 3(6):521-30. PubMed ID: 8789802
[TBL] [Abstract][Full Text] [Related]
14. Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity.
Osada T; Yang XY; Hartman ZC; Glass O; Hodges BL; Niedzwiecki D; Morse MA; Lyerly HK; Amalfitano A; Clay TM
Cancer Gene Ther; 2009 Sep; 16(9):673-82. PubMed ID: 19229288
[TBL] [Abstract][Full Text] [Related]
15. Protease-deleted adenovirus vectors and complementing cell lines: potential applications of single-round replication mutants for vaccination and gene therapy.
Oualikene W; Lamoureux L; Weber JM; Massie B
Hum Gene Ther; 2000 Jun; 11(9):1341-53. PubMed ID: 10890743
[TBL] [Abstract][Full Text] [Related]
16. Generation of recombinant adenovirus vector with infectious adenoviral genome released from cosmid-based vector by simple procedure allowing complex manipulation.
Kojima H; Ohishi N; Yagi K
Biochem Biophys Res Commun; 1998 May; 246(3):868-72. PubMed ID: 9618304
[TBL] [Abstract][Full Text] [Related]
17. Optimization of adenovirus serotype 35 vectors for efficient transduction in human hematopoietic progenitors: comparison of promoter activities.
Sakurai F; Kawabata K; Yamaguchi T; Hayakawa T; Mizuguchi H
Gene Ther; 2005 Oct; 12(19):1424-33. PubMed ID: 15944730
[TBL] [Abstract][Full Text] [Related]
18. Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vector.
Sakurai F; Mizuguchi H; Hayakawa T
Gene Ther; 2003 Jun; 10(12):1041-8. PubMed ID: 12776162
[TBL] [Abstract][Full Text] [Related]
19. The constitutive expression of the immunomodulatory gp19k protein in E1-, E3- adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector.
Lee MG; Abina MA; Haddada H; Perricaudet M
Gene Ther; 1995 Jun; 2(4):256-62. PubMed ID: 7552985
[TBL] [Abstract][Full Text] [Related]
20. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted.
Amalfitano A; Hauser MA; Hu H; Serra D; Begy CR; Chamberlain JS
J Virol; 1998 Feb; 72(2):926-33. PubMed ID: 9444984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
